Table 4.

Incident rate ratio (IRR) and relative 95% confidence interval (CI) by follow-up period and sex, age class and vaccine type and after excluding subjects that had a confirmed SARS-CoV-2 infection after vaccination.

	Population/Subgroup	IRR	95 %CI		p-value
	1–30 days vs 31–60 days
Unadjusted estimate	Overall	0.83	0.76	0.90	<0.0001
Adjusted estimates*	Overall	0.76	0.70	0.83	0.0001
	Sex
	Female	0.79	0.70	0.89	0.0001
	Male	0.73	0.64	0.82	<0.0001
	Age group (years)
	<65$	0.81	0.58	1.12	0.1926
	65–74	0.53	0.40	0.71	<0.0001
	75–84	0.64	0.54	0.76	<0.0001
	>84	0.83	0.74	0.94	0.0024
	Vaccine type
	ChAdOx1-S	0.30	0.16	0.54	0.0001
	Ad26 CoV2-S	0.58	0.07	4.59	0.6055
	mRNA-1273	0.77	0.65	0.91	0.0018
	BNT162b2	0.76	0.68	0.84	<0.0001
	Excluding SARS-CoV-2 infection	0.75	0.69	0.82	<0.0001
	1–14 days vs 31–44 days
Unadjusted estimate	Overall	0.63	0.56	0.71	<0.0001
Adjusted estimates*	Overall	0.62	0.55	0.70	<0.0001
	Sex
	Female	0.67	0.56	0.79	0.0001
	Male	0.57	0.47	0.68	<0.0001
	Age group (years)
	<65$	0.58	0.35	0.96	0.0357
	65–74	0.44	0.29	0.66	0.0001
	75–84	0.50	0.39	0.64	<0.0001
	>84	0.70	0.60	0.83	<0.0001
	Vaccine type
	ChAdOx1-S	0.17	0.06	0.45	0.0004
	Ad26 CoV2-S	0.25	0.01	6.84	0.3755
	mRNA-1273	0.67	0.53	0.85	0.0014
	BNT162b2	0.60	0.51	0.70	<0.0001
	Excluding SARS-CoV-2 infection	0.63	0.55	0.72	<0.0001
	1–7 days vs 31–37 days
Unadjusted estimate	Overall	0.50	0.42	0.60	<0.0001
Adjusted estimates*	Overall	0.50	0.42	0.60	<0.0001
	Sex
	Female	0.60	0.47	0.76	0.0001
	Male	0.41	0.32	0.54	<0.0001
	Age group (years)
	<65$	0.44	0.22	0.88	0.0204
	65–74	0.41	0.22	0.74	0.0031
	75–84	0.38	0.27	0.53	<0.0001
	>84	0.59	0.46	0.76	<0.0001
	Vaccine type
	ChAdOx1-S	0.10	0.01	0.81	0.0347
	Ad26 CoV2-S	0.10	0.01	0.81	0.0347
	mRNA-1273	0.60	0.43	0.83	0.0033
	BNT162b2	0.46	0.37	0.58	<0.0001
	Excluding SARS-CoV-2 infection	0.54	0.45	0.65	<0.0001
	1–3 days vs 31–33 days
Unadjusted estimate	Overall	0.41	0.29	0.56	<0.0001
Adjusted estimates*	Overall	0.38	0.28	0.52	<0.0001
	Sex
	Female	0.44	0.29	0.68	0.0002
	Male	0.34	0.22	0.52	<0.0001
	Age group (years)
	<65$	0.34	0.09	1.38	0.1310
	65–74	0.24	0.08	0.71	0.0094
	75–84	0.23	0.13	0.40	<0.0001
	>84	0.53	0.35	0.81	0.0036
	Vaccine type
	ChAdOx1-S	0.13	0.02	1.10	0.0676
	Ad26 CoV2-S	0.13	0.02	1.10	0.0676
	mRNA-1273	0.76	0.43	1.33	0.3562
	BNT162b2	0.29	0.19	0.43	<0.0001
	Excluding SARS-CoV-2 infection	0.43	0.31	0.59	<0.0001

^*Adjusted for age, day of week and period of vaccination.

^$Age class 18–40 and 41–64 are grouped to increase the number of events.